Anti-epileptic medication and bone health
- 779 Downloads
Epilepsy is a common chronic neurological disorder, usually requiring long-term treatment with anti-epileptic drugs (AED). Many studies have reported that AED therapy is associated with metabolic bone disease and is a major iatrogenic risk factor for fractures. There remains uncertainty about the type(s) of bone disease due to AED treatment, and the pathogenesis of AED-associated fractures.
Deficits in bone mineral density (BMD) are widely reported in AED-treated patient populations. However, much of the research conducted to date has been limited by factors such as small sample size, potentially biased subject selection, a lack of selection of appropriate control data, and failure to take account of important confounding influences. The pathogenesis of AED-associated fractures is likely to be multifactorial, due to factors including reduced BMD, impaired bone quality (due to osteoporosis and/or osteomalacia), increased propensity to fall, and fractures associated with seizures or loss of consciousness.
Patients receiving long-term AED should be monitored for indices of bone health, including BMD and vitamin D status. Lifestyle factors should be optimized, vitamin D status maintained, and fall prevention strategies introduced as appropriate. Good seizure control is important. The use of additional, specific osteoporosis therapy is not evidence-based in this setting, but would appear reasonable in patients with clinically significant decreases in BMD, applying current treatment guidelines for osteoporosis.
There is a pressing need for improved understanding of the pathogenesis of AED-associated bone disease, for better definition of the risk associated with specific AED regimens, and for the development of evidence-based preventive and treatment approaches in this common but neglected disorder.
KeywordsAnti-epileptic drugs Bone mineral density Epilepsy Falls Fractures Metabolic bone disease
This work was supported by the Epilepsy Association, the Victor Hurley Research Fund of Royal Melbourne Hospital, and the Australian National Health and Medical Research Council. Sandra J. Petty was supported by a postgraduate medical research scholarship of the Australian National Health and Medical Research Council.
- 4.Schmid F (1967) Osteopathien bei antiepileptischer Dauerbehandlung. Fortschr Med 85:381–382Google Scholar
- 41.Valimaki MJ, Tiihonen M, Laitinen K, Tahtela R, Karkkainen M, Lamberg-Allardt C, Makela P, Tunninen R (1994) Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J Bone Miner Res 9(5):631–637PubMedCrossRefGoogle Scholar
- 48.Wark JD, Larkins RG, Perry-Keene D, Peter CT, Ross DL, Sloman JG (1979) Chronic diphenylhydantoin therapy does not reduce plasma 25-hydroxy-vitamin D. Clin Endocrinol (Oxf) 11(3):267–274Google Scholar
- 50.Shane E (1996) Osteoporosis associated with illness and medications. In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis. Academic Press, New YorkGoogle Scholar
- 60.Collins N, Maher J, Cole M, Baker M, Callaghan N (1991) A prospective study to evaluate the dose of vitamin D required to correct low 25-hydroxyvitamin D levels, calcium, and alkaline phosphatase in patients at risk of developing antiepileptic drug-induced osteomalacia. Q J Med 78(286):113–122PubMedGoogle Scholar